Australian Clinical Labs Limited

Equities

ACL

AU0000148496

Healthcare Facilities & Services

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-04-30 am EDT			5-day change	1st Jan Change
2.43 ^AUD	-0.82%		+0.83%	-15.92%

Mar. 05	Australia shares inch lower as miners weigh; GDP data in focus	RE
Feb. 28	Australian Clinical Labs Falls 11% After Trimming Interim Dividend on Lower H1 FY24 EPS	MT

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year 2024

August 21, 2023 at 06:20 pm EDT

Australian Clinical Labs Limited provided earnings guidance for the fiscal year 2024. For the year, the company negligible COVID revenue is expected in fiscal year 2024, creating a drag on total revenue growth. As a result ACL believes that it will achieve a similar EBIT result of between $65 million and $70 million.

Latest news about Australian Clinical Labs Limited

Australia shares inch lower as miners weigh; GDP data in focus	Mar. 04	RE
Australian Clinical Labs Falls 11% After Trimming Interim Dividend on Lower H1 FY24 EPS	Feb. 27	MT
Transcript : Australian Clinical Labs Limited, H1 2024 Earnings Call, Feb 28, 2024	Feb. 27
Australian Clinical Labs Slashes Interim Dividend as Underlying H1 FY24 EPS Falls 49%	Feb. 27	MT
Australian Clinical Labs Posts H1 FY24 Revenue Down 6.4% to AU$337.3 Million; Underlying Diluted EPS of AU$0.0511	Feb. 27	MT
Australian Clinical Labs Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Australian Clinical Labs Gets Regulator Approval to Withdraw Healius Takeover Offer	Dec. 26	MT
Australian Clinical Labs Limited cancelled the acquisition of Healius Limited from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.	Dec. 21	CI
Australian shares end higher on miners, Fed rate pivot	Dec. 15	RE
US Fed's Dovish Stance Lifts Australian Shares	Dec. 15	MT
Australian Clinical Labs Intends to Withdraw Proposed Healius Takeover	Dec. 14	MT
Competition Regulator Denies Australian Clinical Labs’ Proposed Takeover of Healius	Dec. 14	MT
Australia shares hit over 4-mth high on boost from commodities, banks stocks	Dec. 14	RE
Australian Clinical Labs to withdraw $1 billion offer for Healius; stocks fall	Dec. 14	RE
Transcript : Australian Clinical Labs Limited - Shareholder/Analyst Call	23-10-22
Australian Clinical Labs Fulfills Conditions for Healius Takeover	23-10-10	MT
Australia Inc roiled by string of cyber attacks since late 2022	23-09-29	RE
Australian Clinical Labs Defers Healius Acquisition EGM	23-09-14	MT
Australian Clinical Labs Chairman to Resume Role	23-09-12	MT
Australian Clinical Labs Limited canceled the acquisition of Healius Limited	23-09-04	CI
Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director	23-08-22	CI
Australian Clinical Labs Lowers Final Dividend as Fiscal 2023 Profit Falls; Shares Plunge 14%	23-08-22	MT
Transcript : Australian Clinical Labs Limited, 2023 Earnings Call, Aug 22, 2023	23-08-21
Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year 2024	23-08-21	CI
Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023	23-08-21	CI

Chart Australian Clinical Labs Limited

Duration

Period

More charts

Company Profile

Australian Clinical Labs Limited is a private provider of pathology services. Its laboratories perform a range of pathology tests each year for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients. It performs a range of services for doctors, patients, and corporate clients, including routine pathology tests, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology and cytopathology, hematology, allergy and immunology, serology and microbiology, infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing. Its specialist services include molecular cancer services, obstetrics and gynecology, pharmacogenetic testing, gastroenterology, and hospital services. It has operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory.

Sector

Healthcare Facilities & Services

Calendar

2024-08-21 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Australian Clinical Labs Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.45 AUD

Average target price

3.096 AUD

Spread / Average Target

+26.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
AUSTRALIAN CLINICAL LABS LIMITED	-15.92%	322M
CVS HEALTH CORPORATION	-14.34%	85.02B
HCA HEALTHCARE, INC.	+14.39%	82.37B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.37%	29.29B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.28%	17.21B
FRESENIUS SE & CO. KGAA	-0.53%	16.7B
QUEST DIAGNOSTICS INCORPORATED	+0.88%	15.5B
FRESENIUS MEDICAL CARE AG	+4.48%	12.15B
EUROFINS SCIENTIFIC SE	-2.51%	12.13B
DAVITA INC.	+32.04%	12.12B

Other Healthcare Facilities & Services